1,966 results match your criteria Veno-occlusive Hepatic Disease


Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis.

Eur J Gastroenterol Hepatol 2020 Jul 3. Epub 2020 Jul 3.

Department of Gastroenterology, Liuzhou People's Hospital, LiuZhou, Guangxi Province, China.

Background: Now there are no efficient prophylactic or treatment strategies for hepatic veno-occlusive disease (VOD). Therefore, it is critical to early identify patients at high risk of VOD.

Aim: To analyze the risk factors of VOD in the hematopoietic stem cell transplantation (HSCT) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001802DOI Listing
July 2020
2.152 Impact Factor

Haploidentical Hematopoietic Stem Cell Transplantation for XIAP Deficiency: a Single-Center Report.

J Clin Immunol 2020 Jul 5. Epub 2020 Jul 5.

Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, P.R., China.

Purpose: X-linked inhibitor of apoptosis (XIAP) deficiency caused by mutations in the XIAP/BIRC4 gene is a rare inherited primary immunodeficiency also known as X-linked lymphoproliferative syndrome type 2 (XLP2). Hematopoietic stem cell transplantation (HSCT) is currently the only curative strategy available. However, few studies of haploidentical HSCT have been published regarding the outcomes in patients with this syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-020-00795-6DOI Listing

Imaging in Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.

Biol Blood Marrow Transplant 2020 Jun 25. Epub 2020 Jun 25.

Department of Hematology, Institut Gustave Roussy, Villejuif, France.

Veno-occlusive disease/sinusoidal obstruction syndrome is a potentially life-threatening complication of hematopoietic cell transplantation. Early diagnosis and, subsequently, earlier intervention have been shown to be beneficial to clinical outcomes. Diagnostic criteria from the European Society for Blood and Marrow Transplantation include recommendations on the use of imaging for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.016DOI Listing

Pathologic Hepatic Contrast-Enhanced Ultrasound Pattern in Patients Undergoing Allogeneic Stem Cell Transplantation.

Ultrasound Med Biol 2020 Aug 2;46(8):1865-1871. Epub 2020 Jun 2.

Interdisciplinary Ultrasound Center, University Hospital Marburg and Philipps University Marburg, Marburg, Germany.

Veno-occlusive disease (VOD) is a severe complication of allogeneic stem cell transplantation (allo-SCT). Its diagnosis is difficult, and ultrasound (US) has not been proven to be of additional diagnostic value. In the work described here, we prospectively analyzed the hepatic contrast-enhanced ultrasound (CEUS) pattern before and after allo-SCT and correlated these results with the pre-allo-SCT VOD risk factors, clinical VOD findings and conventional US findings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ultrasmedbio.2020.03.001DOI Listing

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.

Yonsei Med J 2020 Jun;61(6):452-459

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.

Purpose: Allogeneic hematopoietic stem cell transplantation (HSCT) with optimal conditioning has helped better long-term survival in acute lymphoblastic leukemia (ALL). This study investigated the efficacy and safety of reduced-intensity conditioning (RIC) with busulfan and fludarabine in adult ALL patients unfit for myeloablation.

Materials And Methods: Records of 78 patients who underwent HSCT with RIC consisting of 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3349/ymj.2020.61.6.452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256005PMC

Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.

Int J Hematol 2020 May 28. Epub 2020 May 28.

Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Hepatic veno-occlusive disease (VOD) is a life-threatening complication following hematopoietic stem cell transplant (HSCT). Busulfan has a narrow therapeutic index and its concentration was found to correlate with VOD. Our primary objective was to assess the association between busulfan clearance and VOD in HSCT patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02891-0DOI Listing

Hepatotoxic pyrrolizidine alkaloids induce DNA damage response in rat liver in a 28-day feeding study.

Arch Toxicol 2020 05 17;94(5):1739-1751. Epub 2020 May 17.

German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, 10589, Berlin, Germany.

Pyrrolizidine alkaloids (PA) are secondary plant metabolites that occur as food and feed contaminants. Acute and subacute PA poisoning can lead to severe liver damage in humans and animals, comprising liver pain, hepatomegaly and the development of ascites due to occlusion of the hepatic sinusoids (veno-occlusive disease). Chronic exposure to low levels of PA can induce liver cirrhosis and liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00204-020-02779-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261731PMC

Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD.

Bone Marrow Transplant 2020 May 12. Epub 2020 May 12.

Department of Pediatric Hematology/Oncology and BMT, Wroclaw Medical University, Supraregional Center of Pediatric Oncology "Cape of Hope", Wrocław, Poland.

Hepatic veno-occlusive disease (VOD) is a potentially fatal complication following hematopoietic stem cell transplantation (HSCT). We evaluated in prospective analysis the usefulness of the pediatric EBMT criteria for VOD diagnosis and their presumable impact on cost effectiveness and patients' outcome. Study included all 282 HSCT procedures performed in Department of Pediatric Hematology/Oncology and BMT in Wrocław between January 2016 and March 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0918-1DOI Listing

Unique Mutation in SP110 Resulting in Hepatic Veno-Occlusive Disease with Immunodeficiency.

Case Rep Pediatr 2020 10;2020:3460631. Epub 2020 Jan 10.

Department of Pediatrics, Tawam Hospital, Al-Ain, UAE.

Familial hepatic veno-occlusive disease with immunodeficiency (VODI, OMIM: 235550) is a rare form of combined immune deficiency (CID) that presents in the first few months of life with failure to thrive, recurrent infections, opportunistic infections along with liver impairment. Herein, we are describing a Pakistani patient with a homozygous novel variant in the gene, presenting with classical phenotypic manifestations of VODI. He presented at the age of 3 months with opportunistic infections and later developed liver failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/3460631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199573PMC
January 2020

Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.

Front Immunol 2020 3;11:489. Epub 2020 Apr 3.

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is a rare complication characterized by hepatomegaly, right-upper quadrant pain, jaundice, and ascites, occurring after high-dose chemotherapy, hematopoietic stem cell transplantation (HSCT) and, less commonly, other conditions. We review pathogenesis, clinical appearance and diagnostic criteria, risk factors, prophylaxis, and treatment of the VOD occurring post-HSCT. The injury of the sinusoidal endothelial cells with loss of wall integrity and sinusoidal obstruction is the basis of development of postsinusoidal portal hypertension responsible for clinical syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147118PMC

Can We Improve Our Diagnostic Accuracy with Ultrasonography in Hepatic Veno-Occlusive Disease?

Pediatr Hematol Oncol 2020 May 9;37(4):273-274. Epub 2020 Apr 9.

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08880018.2020.1748352DOI Listing

Sinusoidal obstruction syndrome.

Clin Res Hepatol Gastroenterol 2020 Apr 3. Epub 2020 Apr 3.

Department of Hepatology, DHU Unity, Beaujon Hospital, AP-HP, 100, boulevard du Général-Leclerc, 92118 Clichy, France; French Network for Rare Liver Diseases FILFOIE, Saint-Antoine Hospital, AP-HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France; Reference center of vascular liver diseases, European Reference Network (ERN) 'Rare-Liver', France.

Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease, is characterized by concentric and non-thrombotic obstruction of the sinusoid and central vein lumen with no identified primitive or thrombotic hepatic vein lesions. The initial lesion is a result of endothelial denudation, corresponding to the migration of damaged sinusoidal cells to the central veins of the hepatic lobules, leading to sinusoidal and veno-occlusive congestive obstruction. SOS may be associated with other lesions such as centrilobular perisinusoidal fibrosis, peliosis, or nodular regenerative hyperplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinre.2020.03.019DOI Listing

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

Blood Adv 2020 Apr;4(7):1296-1306

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

At our center, we observed a series of patients who developed transudative refractory ascites secondary to noncirrhotic, non-veno-occlusive disease (VOD)-related portal hypertension after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients were considered to have idiopathic portal hypertension-related refractory ascites (IRA) if they developed ascites secondary to intrahepatic portal hypertension (serum ascites albumin gradient ≥1.1 g/dL or hepatic venous pressure gradient [HVPG] >5 mm Hg), but did not meet the clinical criteria for classical VOD/sinusoidal obstructive syndrome (SOS) and did not have any alternate etiology of portal hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019000638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160275PMC

Conservation of both hematocrit and liver regeneration in hepatectomies: a vascular occlusion approach in rats.

Arq Bras Cir Dig 2020 30;33(1):e1484. Epub 2020 Mar 30.

Department of Surgery, Health Sciences Sector.

Background: Hepatectomies promote considerable amount of blood loss and the need to administrate blood products, which are directly linked to higher morbimortality rates. The blood-conserving hepatectomy (BCH) is a modification of the selective vascular occlusion technique. It could be a surgical maneuver in order to avoid or to reduce the blood products utilization in the perioperative period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0102-672020190001e1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099868PMC

Veno-occlusive disease in children and adolescents after hematopoietic stem cell transplantation: Did the Modified Seattle Criteria fit the characteristics of pediatric population?

Adv Clin Exp Med 2020 Mar;29(3):339-344

Department of Pediatric Hematology/Oncology and Bone Marrow Transplantation, Wroclaw Medical University Supraregional Center of Pediatric Oncology "Cape of Hope", Poland.

Background: Hepatic veno-occlusive disease (VOD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT) and associated with a high mortality rate. Therefore, accurate and immediate diagnosis is crucial for implementing appropriate treatment.

Objectives: In our single-center retrospective study, we assessed the accuracy of the Modified Seattle Criteria in children and adolescents undergoing HSCT, and compared them to the diagnostic criteria recently established by the European Society for Blood and Marrow Transplantation (EBMT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17219/acem/115070DOI Listing

Case 276: Pulmonary Veno-Occlusive Disease and Pulmonary Capillary Hemangiomatosis Disease.

Radiology 2020 Apr;295(1):240-244

From the Department of Radiology, CHU Brugmann, Place A. Van Gehuchten 4, 1020 Brussels, Belgium (C.D., M.W.); and Department of Radiology, CHR Haute Senne, Soignies, Belgium (M.H.).

HistoryA 34-year-old man presented to the emergency department of our hospital for progressive shortness of breath and worsening productive cough of 2 weeks duration. He reported a 10-kg weight loss over 4 months but denied experiencing fever, chills, night sweats, or gastrointestinal, musculoskeletal, or neurologic symptoms. His medical history was unremarkable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2020180473DOI Listing

Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.

Br J Haematol 2020 Mar 10. Epub 2020 Mar 10.

Division of Pediatric Oncology, Department of Pediatrics, Perelman School of Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.

For patients with untreated hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) with multi-organ dysfunction (MOD), mortality is >80%. We conducted a pooled analysis of three studies that assessed Day 100 survival in relationship to MOD severity, with dialysis and/or ventilator dependence representing the most severe organ dysfunction. All patients in the analysis were diagnosed using Baltimore criteria/biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16552DOI Listing

Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Br J Haematol 2020 Mar 4. Epub 2020 Mar 4.

Departments of, Department of, Medicine, Duke University, Durham, NC, USA.

Sinusoidal obstruction syndrome (SOS), previously known as hepatic veno-occlusive disease (VOD), remains a multi-organ system complication following haematopoietic cell transplantation (HCT). When SOS/VOD is accompanied by multi-organ dysfunction, overall mortality rates remain >80%. However, the definitions related to the diagnosis and grading of SOS/VOD after HCT are almost 25 years old and require new and contemporary modifications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16557DOI Listing

Ultrasound in Hepatic Veno-occlusive Disease (HVOD) after Pediatric Hematopoietic Stem Cell Transplantation (HSCT): Comparison of Diagnostic Criteria Including the Pediatric Criteria of European Society for Blood and Marrow Transplantation (EBMT).

Pediatr Hematol Oncol 2020 May 5;37(4):275-287. Epub 2020 Mar 5.

Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

The European Society for Blood and Marrow Transplantation (EBMT) has recently announced new diagnostic criteria for pediatric hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). We retrospectively inspected 97 ultrasound exams of 60 pediatric HSCT patients, and compared its diagnostic value using the Baltimore, Seattle and pediatric EBMT criteria. Nine of the ten patients who were diagnosed as HVOD only in the EBMT criteria had severe or very severe HVOD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08880018.2020.1725199DOI Listing

Detection of pyrrolizidine alkaloids in jamu available on the Indonesian market and accompanying safety assessment for human consumption.

Food Chem Toxicol 2020 Apr 27;138:111230. Epub 2020 Feb 27.

Division of Toxicology, Wageningen University and Research, Stippeneng 4, 6708 WE, Wageningen, the Netherlands.

The occurrence and accompanying risks of pyrrolizidine alkaloids (PAs) in Indonesian jamu were evaluated. PAs were detected in 34 out of 35 jamu containing PA-producing botanicals, in the range of 12.3-235,376 μg/kg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2020.111230DOI Listing

Hepatic veno-occlusive disease may be a rare characteristic of hepatic involvement in systemic amyloidosis: case report and literature review.

J Int Med Res 2020 Feb;48(2):300060520904857

Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060520904857DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110914PMC
February 2020

Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo".

Support Care Cancer 2020 Feb 13. Epub 2020 Feb 13.

Health Professions Direction, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Purpose: Sinusoidal obstruction syndrome (SOS) is one of the most serious complications post haematopoietic stem cell transplantation (HSCT). The diagnosis of SOS is clinical, but nurses should be involved in the pre-transplant risk assessment period and play a crucial role in the early detection of signs and symptoms during and after hospitalization. The aim of this work is to achieve a consensus on nurses' behaviour in caring for SOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-020-05353-9DOI Listing
February 2020

[Proventive and Therapentic Effects of Endothelial Progenitor Cells on Monocrotaline-Induced Hepatic Vein Occlusion Disease].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Feb;28(1):242-247

Department of Hematology, Yuhuangding Hospital, Yantai 264001, Shandong Province, China,E-mail:

Objective: To investigate the preventive and therapeutic effects of endothelial progenitor cells on monocrotaline-induced hepatic vein occlusion disease in mice.

Methods: C57BL/6 mice were randomly divided into 3 groups: saline group (n=15), monocrotaline group (n=15), and endothelial progenitor cell infusion group (n=15). Liver function (TBIL, ALT, AST), liver index, and serum levels of TNF-α and IL-6 were measured on the 8 day after intragastric administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.01.041DOI Listing
February 2020

The long persistence of pyrrolizidine alkaloid-derived pyrrole-protein adducts in vivo: Kinetic study following multiple exposures of a pyrrolizidine alkaloid containing extract of Gynura japonica.

Toxicol Lett 2020 May 23;323:41-47. Epub 2020 Jan 23.

The Ministry of Education Key Laboratory for Standardization of Chinese Medicines and the State Administration of Traditional Chinese Medicine Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai, 201203, China; Shanghai R & D Center for Standardization of Traditional Chinese Medicines, Shanghai, 201203, China.

Gynura japonica (also named Tusanqi in Chinese) is used as a folk herbal medicine for treating blood stasis or traumatic injury. However, hundreds of hepatic sinusoidal obstruction syndrome (HSOS) cases have been reported after consumption of preparations made from G. japonica because it contains large amounts of hepatotoxic pyrrolizidine alkaloids (PAs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2020.01.021DOI Listing

Polycythaemia Vera Presenting As A Porta Hepatis Mass.

J Ayub Med Coll Abbottabad 2019 Oct-Dec;31(4):627-628

Aga Khan University Hospital, Karachi, Pakistan.

Polycythaemia Vera (PV) is a myeloproliferative disorder in which bone marrow has increased production of red blood cells, white blood cells and platelets. The hallmarks of the disease are veno-occlusive events, secondary to increased blood viscosity. Polycythaemia Vera rarely presents with portal vein thrombosis below age of 55 years especially in absence of any chronic liver disease. Read More

View Article

Download full-text PDF

Source

Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.

Biol Blood Marrow Transplant 2020 May 28;26(5):884-892. Epub 2019 Dec 28.

CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:

Gemtuzumab ozogamicin (GO) therapy before allogeneic hematopoietic cell transplantation (alloHCT) has been historically associated with an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with acute myeloid leukemia (AML). The current analysis examined VOD/SOS risk and outcomes in a cohort of patients who in recent years were reported to the Center for International Blood and Marrow Transplant Research. Adults with AML who had GO exposure before myeloablative alloHCT were matched 1:4 by age and disease status at transplant to recipients without GO exposure (control subjects). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.12.763DOI Listing

Ocular hemorrhage secondary to thioguanine-associated veno-occlusive disease in a child with acute lymphoblastic leukemia in delayed intensification.

Pediatr Transplant 2020 02 15;24(1):e13638. Epub 2019 Dec 15.

Pediatric Hematology, Oncology and Bone Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH, USA.

Hepatic VOD is a potentially fatal complication during stem cell transplantation and is rarely seen in the non-transplant setting. We report the case of a five-year-old boy who presented with visual complaints during delayed intensification phase of treatment for ALL. He was found to have bilateral retinal hemorrhages associated with profound thrombocytopenia due to chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13638DOI Listing
February 2020

Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.

Clin J Am Soc Nephrol 2020 02 13;15(2):289-297. Epub 2019 Dec 13.

Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia.

Hematopoietic stem cell transplantation is a life-saving therapy for many patients with cancer, as well as patients with some nonmalignant hematologic disorders, such as aplastic anemia, sickle cell disease, and certain congenital immune deficiencies. Kidney injury directly associated with stem cell transplantation includes a wide range of structural and functional abnormalities, which may be vascular (hypertension, thrombotic microangiopathy), glomerular (albuminuria, nephrotic glomerulopathies), and/or tubulointerstitial. AKI occurs commonly after stem cell transplant, affecting 10%-73% of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.08580719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015091PMC
February 2020

Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement.

Lancet Haematol 2020 Jan 7;7(1):e61-e72. Epub 2019 Dec 7.

Department of Pediatrics, Division of Pediatric Oncology, Stem Cell Transplant, University Hospital of Regensburg, Regensburg, Germany.

Sinusoidal obstructive syndrome, also known as hepatic veno-occlusive disease, is a potentially life-threatening complication that occurs in children undergoing haemopoietic stem-cell transplantation (HSCT). Differences in the incidence of genetic predisposition and clinical presentation of sinusoidal obstructive syndrome between children and adults have rendered the historical Baltimore and Seattle diagnostic criteria insufficient for children. In 2017, the European Society for Blood and Marrow Transplantation (EBMT) proposed the first paediatric diagnostic and severity grading guidelines for sinusoidal obstructive syndrome, intended for implementation across European centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30201-7DOI Listing
January 2020

Defibrotide for the treatment of severe hepatic sinusoidal obstruction syndrome: a single-centre experience.

Eur J Hosp Pharm 2019 Nov 29;26(6):343-346. Epub 2018 Jun 29.

Hospital Pharmacy Department, Hospital Universitario La Paz, Madrid, Spain.

Objectives: Determine the effectiveness and cost of defibrotide in patients with severe hepatic sinusoidal obstruction syndrome following haematopoietic stem cell transplantation in a tertiary hospital.

Methods: A retrospective observational study. Adults or children treated with defibrotide at a mean dose of 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ejhpharm-2018-001575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855847PMC
November 2019

[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].

Zhonghua Xue Ye Xue Za Zhi 2019 Oct;40(10):827-830

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.

To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) containing cladribine sequential busulfan regimen for refractory/relapsed acute myeloid leukemia (AML) . The clinical data of 12 refractory/relapsed AML patients received allo-HSCT with cladribine sequential busulfan regimen. ① Of the 12 patients, 9 were males and 3 females, with a median age of 36 (27-50) years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.10.006DOI Listing
October 2019

Refractory Thrombocytopenia Is a Valid Early Diagnostic Criteria for Hepatic Veno-Occlusive Disease in Children.

Biol Blood Marrow Transplant 2020 Mar 19;26(3):546-552. Epub 2019 Nov 19.

Department Of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio. Electronic address:

We compared the incidence of refractory thrombocytopenia (RT) and platelet transfusion requirements (PTR) in 35 children who developed veno-occlusive disease (VOD) with 35 matched control subjects who underwent hematopoietic stem cell transplant but did not develop VOD. RT developed in 100% of the VOD patients, at a median of 8 days before VOD diagnosis, as compared with 71.5% of the control group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.11.012DOI Listing

Successful Treatment of Veno-occlusive Disease, Transplantation-Associated Thrombotic Microangiopathy, and Acute Graft-vs-Host Disease in a Patient with Relapsed Epstein-Barr Hemophagocytic Lymphohistiocytosis After Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report.

Transplant Proc 2019 Nov;51(9):3159-3162

Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China. Electronic address:

Background: Allogenic hematopoietic stem cell transplantation may be the best currently available method to treat relapsed hemophagocytic lymphohistiocytosis (HLH) related to Epstein-Barr virus. The high rate of transplantation-related complications was initially the main obstacle preventing the wider adoption of this protocol; however, the previously more common complications, such as infection and graft failure, have fallen to very low levels with the development of new drugs and methods. Some other complications, such as veno-occlusive disease and transplantation associated thrombotic microangiopathy, are rare after allogenic hematopoietic stem cell transplantation, but the morbidity and mortality associated with them are very high. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.02.032DOI Listing
November 2019

Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia-Case study from Tahtay koraro district in Tigray region, 2017.

PLoS One 2019 5;14(11):e0224659. Epub 2019 Nov 5.

Mekelle University College of Health Science School of Public Health, Department of Epidemiology, Mekelle, Ethiopia.

Background: Hepatic venous-occlusive disease is blockage of microscopic veins in the liver causing 20-50% mortality. Ingestion of pyrrolizidine alkaloid plant, radiation therapy, and post-bone-marrow-transplant reactions are the commonest causes. In Ethiopia, a venous-occlusive disease outbreak was identified in 2002 in Tahtay Koraro district, Tigray. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224659PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831030PMC

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2020 Mar 31;26(3):529-539. Epub 2019 Oct 31.

Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer, Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

fludarabine with intravenous busulfan at doses of 3.2 mg/kg (Flu/Bu1) or 6.4 mg/kg (Flu/Bu2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.10.024DOI Listing

Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.

Int J Hematol 2019 Dec 13;110(6):709-722. Epub 2019 Nov 13.

Osaka City University, Osaka, Japan.

Inotuzumab ozogamicin (InO) is a targeted treatment for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). InO was previously studied in INO-VATE, an international, open-label, randomized phase 3 trial comparing InO against standard of care (SoC). In the present subgroup analysis, we evaluated outcomes in the 55 Asian patients who were randomized in INO-VATE (31 InO and 24 SoC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02749-0DOI Listing
December 2019
1 Read

Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Semin Thromb Hemost 2019 Nov 18;45(8):767-777. Epub 2019 Oct 18.

Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Defibrotide has been approved in several geographic jurisdictions for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) for years. However, available data on efficacy and safety for its use in VOD are contrasting. We performed a meta-analysis to evaluate the efficacy and safety of defibrotide in the treatment of hepatic VOD/SOS post-hematopoietic stem cell transplantation (HSCT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1698763DOI Listing
November 2019
1 Read

The pyrrolizidine alkaloid senecionine induces CYP-dependent destruction of sinusoidal endothelial cells and cholestasis in mice.

Arch Toxicol 2020 01 12;94(1):219-229. Epub 2019 Oct 12.

Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Ardeystraße 67, Dortmund, Germany.

Pyrrolizidine alkaloids (PAs) are widely occurring phytotoxins which can induce severe liver damage in humans and other mammalian species by mechanisms that are not fully understood. Therefore, we investigated the development of PA hepatotoxicity in vivo, using an acutely toxic dose of the PA senecionine in mice, in combination with intravital two-photon microscopy, histology, clinical chemistry, and in vitro experiments with primary mouse hepatocytes and liver sinusoidal endothelial cells (LSECs). We observed pericentral LSEC necrosis together with elevated sinusoidal marker proteins in the serum of senecionine-treated mice and increased sinusoidal platelet aggregation in the damaged tissue regions. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00204-019-02582-8
Publisher Site
http://dx.doi.org/10.1007/s00204-019-02582-8DOI Listing
January 2020
1 Read

Liquiritigenin and liquiritin alleviated monocrotaline-induced hepatic sinusoidal obstruction syndrome via inhibiting HSP60-induced inflammatory injury.

Toxicology 2019 12 4;428:152307. Epub 2019 Oct 4.

The MOE Key Laboratory for Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines and the SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address:

Hepatic sinusoidal obstruction syndrome (HSOS) is a life-threatening liver disease caused by the damage to liver sinusoidal endothelial cells (LSECs). Liquiritigenin and liquiritin are two main compounds in Glycyrrhizae Radix et Rhizoma (Gan-cao). Our previous study has shown that both liquiritigenin and liquiritin alleviated monocrotaline (MCT)-induced HSOS in rats via inducing the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant signaling pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tox.2019.152307DOI Listing
December 2019

Gynura Segetum Related Hepatic Sinusoidal Obstruction Syndrome: A Liver Disease with High Mortality and Misdiagnosis Rate.

Curr Pharm Des 2019 ;25(35):3762-3768

Department of Liver Diseases, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, 518100, China.

Background And Aim: Gynura segetum (Tusanqi or Jusanqi) is widely used in China as a herbal remedy, however, it has often been associated with hepatic sinusoidal obstruction syndrome (HSOS). Its extent in inducing hepatotoxicity is not sufficiently understood. Hence, we aimed to identify the characteristic features of Gynura segetum associated HSOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612825666191007162024DOI Listing
June 2020
2 Reads
3.452 Impact Factor

Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.

Int J Hematol 2020 Jan 25;111(1):84-92. Epub 2019 Sep 25.

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Aichi, Japan.

Sporadic incidence of veno-occlusive disease (VOD) continues to occur, despite achievement of recommended busulfan (BU) concentrations after real-time BU dose adjustment. To explore the potential influence of glutathione S-transferase (GST) and cytochrome P450 (CYP) genotypes on plasma BU concentration, subsequent VOD, and transplant outcome, we assessed the polymorphisms of multiple GST and CYP genes. Fifty-five patients were included (median age 38 years; range 21-67). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02741-8DOI Listing
January 2020
3 Reads

Retrospective Analysis of 20 Patients with DLBCL Who Received MCVAC Followed by Autologous Peripheral Blood Stem Cell Transplantation.

Gan To Kagaku Ryoho 2019 Aug;46(8):1265-1273

Dept. of Hematology, Juntendo University Urayasu Hospital.

Autologous peripheral blood stem cell transplantation(auto-PBSCT)combined with high-dose chemotherapy has been considered as the standard therapy for relapsed or induction therapy-refractory aggressive lymphomas sensitive to chemotherapy. While various regimens have been applied as the conditioning,none has yet been established as the standard. We have begun to employ high-dose ranimustine,cytarabine,etoposide and cyclophosphamide(MCVAC)regimen. Read More

View Article

Download full-text PDF

Source
August 2019
2 Reads

Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation.

Chemotherapy 2019 4;64(2):57-61. Epub 2019 Sep 4.

Department of Hematology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.

Invasive fungal infections are one of the main infectious complications in allogeneic stem cell transplantation (SCT). Triazoles (voriconazole, posaconazole) are the main prophylactic and therapeutic options for the treatment of invasive aspergillosis. However, pharmacological interactions and hepatotoxicity limit its use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000502279DOI Listing
November 2019
2 Reads

The importance of early intervention in the treatment of hepatic veno-occlusive disease.

Authors:
Antonio Pagliuca

Int J Hematol Oncol 2019 Jul 11;8(2):IJH15. Epub 2019 Jul 11.

Kings College Hospital, Department of Hematology, Denmark Hill, London, SE5 9RS, UK.

Antonio Pagliuca is Professor of hematopoietic stem cell transplantation at King's College London (UK) and medical director at King's College Hospital where, until last year, he had been the transplant director for the past 24 years. He also has roles within NHS England as national clinical lead for regenerative medicine and is a trustee on both the Anthony Nolan trust (London, UK) and Leukemia UK (London, UK). Here he speaks to Commissioning Editor Jennifer Straiton and discusses the interim results of the DEFIFrance study, recently presented at the European Society for Blood and Marrow Transplant (EBMT), which looked at the real-world use of the European Society for Blood and Marrow Transplant severity grading criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh-2019-0003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714065PMC

Rectovaginal Fistula as a Complication of Fecal Management System.

J Investig Med High Impact Case Rep 2019 Jan-Dec;7:2324709619869368

1 Augusta University Medical Center, Medical College of Georgia, Augusta, GA, USA.

We report a rare complication of the use of an intrarectal catheter. An 18-year-old female with T-cell acute lymphoblastic leukemia post-matched unrelated donor allogeneic stem cell transplantation (auto-SCT) developed hepatic encephalopathy secondary to hepatic sinusoidal obstructive disease. A fecal management system was used to contain and divert fecal matter in this immobilized patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709619869368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698988PMC
April 2020
8 Reads

Secondary hemophagocytic syndrome after autologous hematopoietic cell transplant and immune therapy for neuroblastoma.

Pediatr Blood Cancer 2019 11 12;66(11):e27964. Epub 2019 Aug 12.

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.

Secondary hemophagocytic syndrome (HPS) has been described after autologous hematopoietic cell transplant (AutoHCT). We report two cases of secondary HPS after novel consolidation therapy for high-risk neuroblastoma as part of an institutional phase 2 trial incorporating immunotherapy into a "standard" AutoHCT regimen. Both patients developed liver dysfunction beyond expected course of hepatic veno-occlusive disease, coagulopathy, hyperferritinemia, and when evaluated, elevated soluble interleukin-2 receptor and hemophagocytosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27964DOI Listing
November 2019
2 Reads